At the 2022 American Society of Nephrology’s Kidney Week, Seattle-based Chinook Therapeutics recently shared data from their Phase I/II trial evaluating BION-1301, a novel anti-APRIL monoclonal antibody. The company was joined by others showcasing their immunoglobulin A nephropathy (IgAN) related science.
The Chinook study consisted of two cohorts receiving treatment from BION-1301. Results showed that monoclonal antibodies generated rapid and sustained reductions in IgAN and galactose-deficient IgA1 (Gd-IgA1) levels.
This is a significant moment for efforts like Chinook’s to conquer IgAN — it’s estimated that 400,000 people in the U.S. and Europe suffer from it, and half of that population could develop end-stage renal disease two decades from the initial diagnosis, potentially leading to the need for dialysis or a kidney transplant.